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Abstract
Background: Fibrosis is a major contributor to systemic sclerosis (SSc)-related morbidity, and rapid, progressive skin
involvement predicts later mortality. Western medicine therapies for SSc cannot produce satisfactory effects currently,
while Traditional Chinese Medicine (TCM), such as the Wenyang Huazhuo Tongluo (WYHZTL) formula, a Chinese herbal
decoction, has shown amazing anti-fibrosis efficacy on SSc in clinical applications. This study is aiming to investigate
the anti-fibrotic mechanism of WYHZTL formula for the treatment of SSc.
Methods: Fibroblasts from primary culture of skin lesions of SSc patients were exposed to rat medicated sera containing
WYHZTL or XAV939, a small-molecule inhibitor of both tankyrase 1/2 and Wnt/β-catenin pathway. Cell counting kit-8
assay and Annexin V FITC/PI apoptosis kit were used to analyze cell proliferation and apoptosis in fibroblasts, respectively.
Reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to detect the mRNA and
protein levels of cyclin D1 and survivin.
Results: After 28, 48 and 72 h of incubation, the proliferative ability of the fibroblasts cells was obviously reduced by the
sera containing WYHZTL compared with that in the control group; the percentage of apoptotic cell population in the
sera containing WYHZTL treated fibroblasts cells was significantly higher than that in those treated with the control sera,
and was about similar to that in those treated with XAV939. The sera containing WYHZTL could down-regulate both
mRNA and protein levels of cyclin D1 and survivin, compared with the control group.
Conclusions: The present study demonstrates the antiproliferative and pro-apoptotic actions of WYHZTL formula against
fibroblasts and the effect may be related to the down-regulation of mRNA and protein levels of cyclin D1 and survivin
in SSc.
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Background
Systemic sclerosis (SSc) is an autoimmune and/or autoin-
flammatory disease mainly characterized by the excessive
accumulation of extracellular matrix (ECM), especially as
collagen, and by extensive fibrosis in skin and eventually
in multiple internal organs, such as lung, heart, esophagus
and kidney [1]. Genetic factors, infection and unknown
environmental influences may play roles in the pathogen
of the disease. However, the exact initiating events that
lead to the disease remain unclear. Immune dysfunction,
vascular damage, abnormal metabolism of connective tis-
sue and a complex interaction of them are thought to be
involved in SSc. Fibrosis is a major contributor to the
disease related morbidity, and rapid, progressive skin in-
volvement predicts later mortality [2]. Western medicine
therapies mainly include immunosuppressive agents, vaso-
active drugs and connective tissue formation inhibitors.
However, the clinical effects of these therapies are of ques-
tionable significance currently, such as methotrexate and
cyclophosphamide [3, 4].
Considering the unsatisfactory effect of current ther-
apies for SSc, it would be desirable to have novel drugs/
therapies. Traditional Chinese medicine (TCM) has a
long history of dealing with diseases and evolved over
the past two and a half millennia to become the second
largest health-care system in the world, after modern
Western medicine. In the past few years, much research
has focused on the molecular mechanisms of TCMs to
treat different diseases, for example, Shuang Kou et al.
[5] reported that Zuo-Gui and You-Gui pills exerted
neuroprotective effects by downregulation of NogoA,
NgR, and RhoA pathways in rats with experimental
autoimmune encephalomyelitis. Some effective TCM
formulas have also been found to treat SSc through
acting on certain molecular targets. Yan et al. [6] re-
ported that Wenyang Chubi Decoction had the effects in
decreasing the connective tissue growth factor and
collagen-I expression and improving the skin fibrosis in
a mouse model of SSc. Yiqihuoxue formula was found
to effectively reduce collagen production via down-
regulating the phosphorylation of Smad3 and then the
activity of Smad binding element, which are involved in
the TGF-beta pathway and constitutively activated in the
progression of SSc [7].
Wenyang Huazhuo Tongluo (WYHZTL) is a patented
formula (No. CN201310351880.2) to treat SSc owned by
our team, and has shown the efficacy of anti-fibrosis in
clinical applications. Our previous studies proved that it
exerts its therapeutic effect on SSc patients by regulating
Th17/Treg imbalance, lowering levels of von Willeb-
rand factor (vWF) and aminoterminal propeptide of
type III procollagen (PIIINP), and elevating the level of
cross-linked carboxyterminal telopeptide of type I colla-
gen (I CTP) [8]. We also reported that the formula
antagonizes the fibrosis in a mouse SSc model through
its regulation of TGF-β1 /Smad signal pathway and the
reduction of collagen content [9]. We also have demon-
strated that the sera containing WYHZTL reduces the
expression levels of collagen I/III through regulating
some key signal molecules, such as TGF-β1 receptor I,
p-Smad2/3, Smad7, in TGFβ1/Smad Signaling pathway
of skin fibroblasts obtained from SSc patients [10]. In
another report, we found the sera containing WYHZTL
inhibits the proliferation of SSc skin fibroblasts via
blocking the cell cycle transition from the G1 to S phase
[11], but the exact mechanism is still unclear. Therefore,
further study on the role of WYHZTL in fibrosis of SSc is
needed. It’s known that the cell cycle transition from the
G1 to S phase is regulated by cyclin D1, and cyclin D1
activation promotes the passage of cells through the G1
restriction checkpoint [12, 13]. Apoptosis is a key mech-
anism involved in fibrosis of SSc [14], and survivin is an
inhibitor of apoptotic protein gene family and a cell cycle
regulator, it is critically required for suppression of
apoptosis and ensuring normal cell division in the G2/M
phase of the cell cycle [15].
In order to address the anti-fibrotic mechanism of
WYHZTL formula in treating SSc, a novel seropharma-
cology method arising recent years for pharmacological
study is taken to study TCM in vitro using animal-
medicated sera [16]. The essence of seropharmacology is
to administrate TCM to experimental animals (generally
are rabbits or rats), followed by harvesting animal sera
after a period of time. Then the sera are applied to
different cell lines for molecular mechanism study. The
advantage of seropharmacology for TCM study is to use
the real pharmaceutical ingredients or internal biological
metabolic compounds of TCM, without isolating the
individual components, which is neither difficulty nor
necessary in some cases.
The aim of the present study is to investigate the
mechanism of WYHZTL formula against fibrosis in SSc
regarding its effect on the expression and regulation of
cyclin D1 and survivin in primary cultured human fibro-
blasts treated by the animal-mediated sera.
Methods
Composition and preparation of Wenyang Huazhuo
Tongluo formula
The ingredients of WYHZTL formula were purchased
from the First Affiliated Hospital of Nanyang Institute of
Technology and the full ingredients are Radix Astragali
membranacei, Herba Epimedii, Ramulus Cinnamomi
cassiae, Herba Glechomae longitubae, Semen Sinapis
albae, Radix Dioscoreae oppositae, Radix Codonopsitis
pilosulae, Radix Rehmanniae praeparata, Fasciculus vas-
cularis Luffae and Capparis zeylanica Linn. All of the
ingredients of WYHZTL were prepared as crude slices
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and boiled twice (90 min per time) with ultrapure water
as the doctor’s directions. The water extracts were com-
bined, filtered and evaporated under reduced pressure to
a final concentration of 1.5 g/mL based on the equiva-
lent amount of the crude drugs.
Cell culture
Skin biopsy specimens were obtained from five progres-
sive SSc patients, who had the disease course of less
than 2 years and were fulfilled the American College of
Rheumatology criteria for SSc [17]. Biopsy specimens
(3 mm × 3 mm) were performed at the edge of the lesion
of each SSc patient. All patients provided written con-
tents, and the study was approved by the Ethics Com-
mittee of Nanyang Institute of Technology, China.
Skin samples were transported in DMEM supplemented
with 10 % fetal bovine serum (FBS), 100 IU/mL penicillin,
and 100 mg/mL streptomycin for processing the same
day. The skin samples were washed in 75 % ethanol, phos-
phate buffered saline (PBS), and the DMEM supplement.
Cultured fibroblasts were established by mincing tissues
and placing them into 60-mm culture dishes secured by
glass coverslips. Third-to sixth-passage fibroblasts were
used for gene and protein expression assays.
Preparation of rat medicated sera
The rat medicated sera was prepared according to the
published protocols [18]. Briefly, 30 Wistar female rats,
aged between 6 and 8 weeks old and weighing 220 ~
250 g, were divided into WYHZTL (N = 15) and control
(N = 15) groups. The animals were supplied by the
Henan Experimental Animal Center (Zhengzhou, China)
and maintained in accordance with accepted standards
of humane animal care as outlined in ethical guidelines
for care and use of laboratory animals in an air-conditioned
room with controlled a temperature of 22 ± 2 °C, a humid-
ity level of 45 % to 65 %, and a 12/12 h light/dark cycle.
The rats in WYHZTL group were individually adminis-
trated by gavage with WYHZTL decoction of 6.25 g/kg/day
based on clinical dosage. The control group received
deionized water. After 10 days of administration, blood was
collected from retinal venous plexus and centrifuged. The
collected sera were aliquoted into 5 mL Eppendorf tubes
and preserved at-80 °C for future use.
Sera samples preparation for HPLC analysis
One milliliter of the rat medicated sera were mixed with
5 mL of methanol and ultrasonicated for 20 min. The
mixture was then centrifuged at 3000 rpm for 10 min at
room temperature, and the supernatant was evaporated
to dryness under a steam of nitrogen at 50 °C. The resi-
dues were reconstituted in 100 μL of methanol and
filtrated through a 0.45 μm membrane filter (Millipore
Co. Ltd., Tokyo, Japan), and an aliquot (20 μL) was
applied to the HPLC analysis. The HPLC analysis was
performed with a Waters Alliance 2695 HPLC system.
The HPLC conditions were as follows: column: Agilent
C18 column (150 mm× 4.6 mm); column temperature:
30 °C; mobile phases: 0.1 % ammonium acetate (A) and
linear gradient system of methanol (B), where A/B: 85/15
(0 min), 70/30 (5 min), 30/70 (10 min), 30/70 (16 min),
and 85/15 (28 min); flow rate: 1 mL/min; detection wave-
length: 259 nm; and injection volume: 20 μL.
Proliferation assay
Cell proliferation was analyzed with the cell counting
kit-8 (CCK-8; Santa Cruz Biotechnology, USA) assay.
Briefly, the fibroblast cells were harvested in exponential
growth and seeded into 96 well plates at a density of
1.0 × 104 cells per well. The supernatant was removed
after cell adhered to the wall and added FBS-free
DMEM medium to incubate another 24 h. And then the
cells were treated with the rat medicated control sera,
the WYHZTL sera or XAV939 (final concentration
2 ng/mL; Sigma-Aldrich), a small-molecule inhibitor of
tankyrase 1/2 and Wnt/β-catenin pathway, plus the
WYHZTL sera respectively. The sera volume ratio for
incubation is 15 %. After incubated 24, 48 and 72 h,
CCK-8 was added into the cells at a volume rate 1:10 to
incubate for 2.5 h. The absorbance was measured at
450 nm using an enzyme immunoassay analyzer (Dyna-
tech MR4100, USA). The proliferation rate was calculated
for each well. The mean and standard deviation of five
relative proliferation rates for each well were calculated.
The cell morphology was observed under an inverted
microscope during the experimentation.
Measurement of apoptosis by flow cytometry
Analysis of apoptosis percentage was performed using
an Annexin V-FITC/PI apoptosis kit (KeyGen Biotech,
China) as previously described protocol [19]. Briefly, the
cells were incubated with the rat medicated control sera,
the WYHZTL sera and XAV939 plus the WYHZTL sera
respectively for 24, 48 and 72 h. The sera volume ratio is
same as above. When reaching 80 % confluence, cells
were trypsinized, washed with PBS and resuspended in
500 μl of Annexin V-binding buffer. A mixture of 5 μl of
FITC-labeled Annexin V plus 5 μl of Propidium Iodide
(PI) solution was then added into the cells to incubate
for 15 min at room temperature in the dark prior to flow
cytometry analysis. Cell apoptosis was analyzed using
CellQuest software (Becton-Dickinson). Three separate
experiments were performed for each clone.
Western blot analysis
The effects of the rat medicated sera containing WYHZTL
on cyclin D1 and survivin protein expression was analyzed
as previously described protocol with slightly modification
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[20]. Briefly, the fibroblast cells were treated with the sera
as above at a density of 1.0 × 109 cells per 25 ml culture
flask for 24, 48 and 72 h, and then the cells were lysed
using RIPA lysis buffer (Beyotime Institute of Biotech-
nology, China). The protein concentrations were deter-
mined using the bicinchoninic acid assay (BCA; Santa
Cruz Biotechnology, USA). A total of 40 μg of proteins
was electrophoresed via sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE), and trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
(Millipore, USA), which were then blocked with 5 %
skimmed milk powder for 1 h at room temperature. The
membranes were incubated with antibodies against cyclin
D1 and survivin (1: 1000 dilution; Santa Cruz Biotechnol-
ogy, USA), followed by incubation with corresponding
horseradish peroxidase (HRP)-conjugated secondary anti-
body at a 1:5000 dilution for 1 h at 37 °C . Finally, the
membranes were washed with PBS three times and the
immunoreactive bands were visualized using an ECL-
PLUS/Kit according to the manufacturer’s instructions.
The optical density of each band was measured with a
computer-assisted imaging analysis system (Quantity One,
Bio-Rad, Hemel Hempstead, UK) and the relative protein
levels were normalized to optical density of β-actin.
RT-PCR analysis
Total RNA from individual groups was extracted using
the TRIzol reagent (Invitrogen, USA). All RNA prepar-
ation and handling steps took place in a laminar flow
hood, under RNAse-free conditions. The isolated RNA
from each fraction was dissolved in 20 μL of RNAse-free
water and stored at-80 °C until used. cDNA synthesis
was performed at 37 °C for 15 min and 85 °C for 5 sec
using the Primer Script RT reagent Kit (TaKaRa Biotech-
nology, Dalian, China) in a total volume of 20 μL according
to the manufacturer’s instructions. The forward and
reverse primers for amplifying cyclin D1 are as follows: 5′-
CGATGCCAACCTCCTCAAC-3′ and 5′-AAGCCTTGT
AATCCTTGTG-3′, and the length of the amplified frag-
ment was 212 bp. The forward and reverse primers for
amplifying survivin were as follows: 5′-GGACCACCG
CATCTCTACA-3′ and 5′-GCACTTTCTTCGCAGTTT
CC-3′, and the length of the amplified fragment was
338 bp. A 196-bp fragment of GAPDH was used as the
internal control and was amplified with the following for-
ward and reverse primers: 5′-GAGTCAACGGATTTG
GTCGT-3′ and 5′-GACAAGCTTCCCGTTCTCAG-3′.
The PCR cycling conditions comprised a denaturation step
for 5 min at 95 °C, followed by 30 cycles of denaturation
(94 °C for 15 s), annealing (55 °C for cyclin D1, 54 °C for
survivin and 57 °C for GAPDH for 30s), and extension
(72 °C for 30s). After the last cycle, all PCR products were
subjected to a final extension for 10 min at 72 °C. PCR
products were combined and then electrophoresed on
1.5 % agarose gels containing ethidium bromide; the
images were captured using a Gel Doc XR+ Image Station
(Bio-Rad, Hemel Hempstead, UK). The optical density of
each band was measured with Quantity One and normal-
ized to optical density of the housekeeping gene GAPDH.
Statistical analysis
Data were analyzed with SPSS 16.0. Statistical data are
expressed as mean ± SD. Group comparisons were per-
formed using one-way ANOVA followed by a Tukey test
for multiple comparisons. The results were considered
statistically significant when P < 0.05. Graphic represen-
tation was performed using GraphPad Prism version
6.01 for Windows (GraphPad Software, San Diego CA,
USA, www.graphpad.com).
Results
Analysis of the compounds absorbed into the blood after
oral administration of WYHZTL decoction in SD rats
Figure 1 shows the representative HPLC profiles of the
control rat sera and the rat medicated sera, respectively.
Four distinct peaks can be detected in the rat medicated
sera containing WYHZTL compared with the control
rat sera, which indicates that the rat medicated sera may
contain active ingredients and/or metabolic components
of the decoction.
Effect of rat medicated sera containing WYHZTL on
proliferation of fibroblasts
In order to confirm the role of WYHZTL formula in the
proliferation of fibroblasts, the rat medicated sera con-
taining WYHZTL were added into the primary culture
fibroblasts. The morphology of the cells was observed
directly under an inverted microscope. In the control
group, fibroblasts were numerous and having branched
cytoplasm surrounding elliptical, speckled nucleus with
two or more nucleoli. Most nucleoli were spindle and
some were irregular, but all tended to be in the same
direction. After incubated with XAV939 or the sera
containing WYHZTL, both the total cell and the irregu-
lar cells with multi-nucleoli decreased, the cell bodies,
nucleoli and the branched cytoplasm were shorter,
compared with those in the control group (as shown in
Fig. 2a). Such results demonstrated that the sera contain-
ing WYHZTL strongly implicated in cell morphology
regulation and had inhibitory effect on proliferation in
fibroblasts.
The above evidence was further confirmed by CCK-8
assay. After incubated with the rat medicated sera or
XAV939 for 28, 48 and 72 h, the proliferative ability of
the fibroblasts cells was markedly reduced and was
significantly lower than that in the control group fol-
lowing the indicated time of incubation (P < 0.01), as
shown in Fig. 2b.
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Fig. 1 HPLC profiles of the rat medicated sera after administrated by gavage of the WYHZTL decoction. a Control rat sera; b rat medicated sera
after administrated by gavage 1 h. Four distinctive peaks (1, 2, 3 and 4) are detected in the rat medicated sera, but not in the control rat sera.
This indicates that the rat medicated sera may contain active ingredients and/or metabolic components of the WYHZTL decoction
Fig. 2 Effect of Rat Medicated Sera containing WYHZTL on proliferation of fibroblasts. a Cell morphology observation: cells cultured in DMEM
containing the sera were grown in the flask and viewed directly under the Nikon Phase Contrast Inverted Microscopy (200× original magnification;
Ti-S type, Nikon Co., Japan). b The CCK-8 assay was performed to examine cell proliferation. The absorbance measured at 450 nm by using an enzyme
immunoassay analyzer (Dynatech MR4100, USA) after incubated for 24, 48 and 72 h. The mean and standard deviation of 5 relative proliferation rates
for each well were calculated. C represents control group, N represents XAV939 inhibitor group, X represents rat medicated sera containing WYHZTL
group. **P < 0.01 compared with each group
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Rat medicated sera containing WYHZTL promotes
apoptosis in fibroblasts
In order to determine the effects of the rat medicated
sera containing WYHZTL on apoptosis in fibroblasts,
viable, early apoptotic, and late apoptotic or necrotic
cells can be distinguished by flow cytometry analysis
using dual staining with Annexin V/PI dyes. As shown
in Fig. 3a, viable cells were PI and Annexin V-FITC
double negative; apoptotic cells were Annexin V-FITC
positive and PI negative, whereas late apoptotic or
necrotic cells were Annexin V-FITC and PI double
positive. We observed a strong time-dependent
relationship with regard to the rat medicated sera
containing WYHZTL or XAV939 exposure and early
apoptotic or late apoptotic cells (Fig. 3b, c). The per-
centage of late apoptotic cell population in the sera
containing WYHZTL treated cells was clearly higher
than that in those treated with the control sera and
was slightly lower than that in those treated with
XAV939 (P < 0.01). Interestingly, the percentage of
early apoptotic cell population in the sera containing
WYHZTL treated cells was clearly higher than that in
those treated with XAV939 (P < 0.01), which suggest-
ing the rat medicated sera containing WYHZTL pro-
motes apoptosis, especially early apoptosis, in the
fibroblasts. This effect was also observed in XAV939
treated cells.
Effect of rat medicated sera containing WYHZTL on cyclin
D1 in fibroblasts
In order to further explore the molecular mechanisms of
the role of the rat medicated sera containing WYHZTL,
we focused on the recognized proliferation-associated
gene cyclin D1. RT-PCR and Western blotting were per-
formed to determine the cyclin D1 mRNA and protein
levels after treated with the rat medicated sera contain-
ing WYHZTL in fibroblasts. As shown in Fig. 4, treated
with the rat medicated sera containing WYHZTL for 24,
48 and 72 h led to a down-regulation of cyclin D1
mRNA and protein expression compared with that in
the control group (P < 0.01), in accordance with the
effect of XAV939 known to have inhibition action on
cyclin D1 (P > 0.05). These results indicated that the sera
inhibited proliferation in fibroblasts through down-
regulation of cyclin D1 in mRNA and protein level.
Effect of rat medicated sera containing WYHZTL on
survivin in fibroblasts
The role of the rat medicated sera containing
WYHZTL on the recognized apoptosis-associated gene
survivin was examined by RT-PCR and Western blot-
ting in fibroblasts. As shown in Fig. 5, treating with the
rat medicated sera containing WYHZTL led to a down-
regulation of survivin mRNA and protein expression
compared to the control group (P < 0.01). The sera had
Fig. 3 Rat medicated sera containing WYHZTL induces cell apoptosis in fibroblasts. a Cell apoptosis was examined after incubation for 48 h by
Annexin V-PI staining using flow cytometry. Representative results are shown. b Bar graph of early apoptosis rate after incubated with the sera or
XAV939 for 24, 48 and 72 h. c Bar graph of late apoptosis rate after incubated with the sera or XAV939 for 24, 48 and 72 h. C represents control group,
N represents XAV939 inhibitor group, X represents rat medicated sera containing WYHZTL group. **P < 0.01, ***P < 0.001 compared with each group.
The results are the mean ± SD of 3 independent experiments
Han et al. BMC Complementary and Alternative Medicine  (2016) 16:69 Page 6 of 9
a similar inhibitory effect on fibroblasts to XAV939
although the former is weaker than the later (P > 0.05).
These results indicated that the sera promoted apop-
tosis in fibroblasts via down-regulation of survivin in
both mRNA and protein levels.
Discussion
SSc is a chronic fibrosing connective tissue disease charac-
terized by a higher mortality rate compared with other
connective tissue diseases. In early stages of SSc, the main
pathological manifestations are perivascular inflammatory
infiltrates and a reduced capillary density, whereas later
stages are fibrosis characterized by an excessive accumula-
tion of collagen-rich ECM. The fibrosis disrupts the
physiological structure of the affected tissues and inter-
feres with proper organ function. Tissue fibrosis is the
primary cause of SSc-related mortality presently and the
10-year survival rate is as low as 54 % - 66 % [21]. There is
a high unmet clinical need for effective antifibrotic therap-
ies in SSc, but no drugs have been clearly shown to be
effective in reducing specifically the development of SSc
fibrosis in clinic up to now [4, 22].
Chinese medical treatment is aimed at adjusting the
environmental and human influences through the use of
TCM, which exerts a comprehensive effect on the dis-
eases; because the decoction is usually composed of sev-
eral herbs or minerals according to the symptoms of
patients. WYHZTL formula is composed of 10 herbs,
among which Radix Astragali membranacei exerts an
anti-fibrotic effect in rats induced by porcine serum via
down-regulating PDGFR-β, inhibiting hepatic stellate
cells proliferation and MAPK activation [23]. One of the
isolated constituents from Herba Glechomae longitubae,
asiatic acid, inhibits TGF-β1-induced collagen and PAI-1
expression in keloid fibroblasts through PPAR-γ activa-
tion [24]; Radix Dioscoreae oppositae attenuats CCl (4)-
induced hepatic fibrosis in rats in a dose-dependent
manner and the attenuation may be related to the anti-
oxidant properties of Radix Dioscoreae oppositae [25].
The ethanolic extract of Capparis zeylanica Linn was
reported having anti-fibrotic effect via inhibiting the
fibroblast proliferation and type I collagen production in
SSc [26]. However, the therapeutic action of a TCM
formula is far more than that of the total sum of its
components, it’s a very complicated process in vivo.
TCM formulas prescribed by doctors of Chinese medi-
cine are selected on the basis of the past experience with
treating diseases and on the basis of the current health
Fig. 4 Effect of down-regulation of cyclin D1 by the rat medicated sera containing WYHZTL in fibroblasts. a The mRNA levels of cyclin D1 were
detected by RT-PCR after treated with the sera containing WYHZTL for 24, 48 and 72 h. GAPDH was applied as an endogenous control and densitometric
values were normalized by GAPDH. b The protein levels of cyclin D1 were detected by Western blotting after treated with the sera containing WYHZTL
for 24, 48 and 72 h. β-actin was used as an endogenous control and densitometric values were normalized by β-actin. Representative results are shown.
C represents control group, N represents XAV939 inhibitor group, X represents Rat Medicated Sera containing WYHZTL group. Densitometric values are
shown as mean ± SD. Left panels represent RT-PCR/Western blotting gel results, right panels represent bar graphs for relative mRNA and protein levels
for cyclin D1. *P< 0.05, **P< 0.01, compared with the control group. The results are the mean ± SD of at least 5 independent experiments
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status of the individual patient. Not only do the symp-
toms of SSc vary from individual to individual, but also
the health histories (such as coexisting diseases or
syndromes) are different. These factors must be
accounted in determining suitable prescriptions. Thus,
TCM approach is a comprehensive treatment based on
individual needs.
Known abnormalities in SSc that relate to the fibrotic
response include fibroblast proliferation increased and
apoptosis decreased [27]. So one of treatment strategies
for fibrosis in SSc is to inhibit proliferation and promote
apoptosis. Cyclins play an important role in cell progres-
sion of fibrosis, so the mRNA and protein levels of cell
cycle regulatory factor, cyclin D1, were examined. Our
results showed that incubation with WYHZTL formula
in fibroblasts caused a marked reduction of the mRNA
and protein levels of cyclin D1, indicating its crucial for
the G1 to S transition [12, 13] and suppression of apop-
tosis [28]. Marsillach et al. reported that survivin expres-
sion is significantly increased during the development of
fibrosis [29]. Consistently, Sisson et al. reported that
inhibition of survivin restores susceptibility of fibroblasts
to Fas-mediated apoptosis. Therefore, survivin may rep-
resent a potential target for anti-fibrotic therapies [30].
Additionally, survivin is critically required for suppres-
sion of apoptosis and ensuring normal cell division in
the G2/M phase of the cell cycle [15]. Our results
showed that WYHZTL formula incubation in fibroblasts
also caused significant reduction of the mRNA and pro-
tein levels of survivin. We have reported that WYHZTL
formula has the effect of inhibition on proliferation of
SSc skin fibroblasts via blocking the cell cycle transition
from the G1 to S phase previously [11]. Therefore, our
study suggested that WYHZTL formula arrested the cell
cycle in the phase by inhibiting cyclin D1 expression,
and its anti-fibrosis effect related to inhibition of cylcin
D1 and survivin.
XAV-939 is screened out as an inhibitor of Wnt/β-
catenin pathway and demonstrates to stabilize the axin
levels through inhibiting tankyrases, and consequently
inhibits the Wnt signaling and the expression of target
genes, including survivin and cyclin D1 [31]. Aberrant
Wnt/β-catenin signaling pathway due to gain of β-
catenin function, induces constitutive transcription of
cyclin D1 [28, 32]. Our results showed that the effect of
WYHZTL formula on survivin and cyclin D1 is consist-
ent with that of XAV939, this further proves that the
anti-fibrosis effect of the formula is related to the inhib-
ition of cylcin D1 and survivin.
Conclusions
In summary, our study demonstrates the WYHZTL for-
mula has antiproliferative and pro-apoptotic actions on
fibroblasts in SSc. It also provides valuable information
Fig. 5 Effect of down-regulation of survivin by the rat medicated sera containing WYHZTL in fibroblasts. a The mRNA levels of survivin were detected by
RT-PCR after treated with the sera containing WYHZTL for 48 h. GAPDH was applied as an endogenous control and densitometric values were normalized
by GAPDH. b The protein levels of survivin were detected by western blotting after treated with the sera containing WYHZTL for 48 h. β-actin was used as
an endogenous control and densitometric values were normalized by β-actin. C represents control group, N represents XAV939 inhibitor group, X
represents rat medicated sera containing WYHZTL group. Representative results are shown. Densitometric values are shown as mean ± SD.
Left panels represent RT-PCR/Western blotting gel results, right panels represent bar graphs for relative mRNA and protein levels for survivin.
*P < 0.05, **P < 0.01. The results are the mean ± SD of at least 5 independent experiments
Han et al. BMC Complementary and Alternative Medicine  (2016) 16:69 Page 8 of 9
regarding the mechanism of repression of SSc fibrosis,
and the effect may be related to the down-regulation of
mRNA and protein levels of cyclin D1 and survivin in
SSc. Nevertheless, further studies on the other possible
mechanisms of anti-fibrosis effect of WYHZTL formula
and on the actual active ingredients and/or biotrans-
formed ingredients contributed to the anti-fibrosis effect
of WYHZTL are needed.
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